Diabetes Care Review Time

ADA's official pages are strong on article requirements, clinical-trial reporting, and submission mechanics. On timing they publish one figure on the journal's About the Journal page, an average time to first decision of 18 days, and they do not publish stage-by-stage medians. ADA updates that page each July and August.

The published peer-review process has these steps:

• the Editor-in-Chief assesses whether the content and subject suit the journal

• only manuscripts with a priority score above the 50th percentile are reviewed

• an Associate Editor invites expert reviewers and recommends a decision based on the reviews of three peer reviewers

That model matches the journal's editorial identity. Diabetes Care is trying to decide whether the paper actually changes diabetes management, outcomes, prevention, or implementation, and the Editor-in-Chief makes that call first.

That is why the first read matters so much at Diabetes Care. The journal is not simply sending files out quickly and letting reviewers sort them. It is doing a large amount of selection internally first.

The central editorial question at Diabetes Care is unusually specific: is the manuscript fundamentally about diabetes care, or is diabetes only the population in which the study happened?

That makes the pre-review stage weighty. Editors can spend time on manuscripts that are:

• clinically polished but not actually diabetes-care centered

• statistically sound but too small for meaningful clinical endpoints

• mechanistically interesting but weak on human validation

• relevant to metabolism or endocrinology broadly without enough diabetes-management consequence

• hard to generalize beyond one narrow practice setting or population

So the editorial screen is not random. It is the journal protecting a strong clinical identity.

The common causes are:

• diabetes is the setting rather than the actual clinical problem

• endpoints are statistically significant but not clinically meaningful

• the cohort is too narrow to support practice-wide conclusions

• the paper leans on surrogate or mechanistic logic without enough human outcome relevance

• reviewer and editor concern that the work belongs in Diabetes, Diabetologia, or another related journal instead

When Diabetes Care gets slower, it is often because the manuscript is close enough to debate but not yet obvious enough to move cleanly.

For year-over-year citation data, see the diabetes care citation metrics page.

Diabetes Care is up from 14.8 in 2023 to 16.6 in 2024, which reinforces that the journal remains one of the most visible homes for clinical diabetes work. The combination of a high citation metrics, strong 5-year JIF, and high SJR means the journal does not need to compromise on scope to stay busy.

For review time, that usually translates into a stronger internal editorial screen. The journal can take time deciding whether the paper really deserves its audience.

Even strong planning data hide several things:

• some papers die in under two weeks, which can make community medians hard to interpret

• the editorial review stage is often doing more work than the reviewers

• a first decision can still be a major-revision outcome rather than a near-accept

• timing does not tell you whether the endpoint choice was clinically persuasive enough

So review speed matters, but editorial fit matters more.

In our pre-submission review work, the biggest timing mistake is assuming that "diabetes-related" is good enough. Diabetes Care usually wants something stricter: a paper that clearly changes diabetes prevention, treatment, monitoring, outcomes, or care delivery.

The manuscripts that move best through the journal usually have:

• diabetes as the actual clinical problem being solved

• clinically meaningful endpoints, not only statistically positive ones

• a cohort and design large enough for the central claim

• enough generalizability that readers can imagine using the result in practice

That combination tends to justify the review path. Without it, the process becomes mostly expensive waiting.

For Diabetes Care-targeted manuscripts, three patterns most consistently predict slow review at Diabetes Care (American Diabetes Association). Of manuscripts we screened in 2025 targeting Diabetes Care and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: Diabetes Care editors enforce practice-relevance threshold; mechanistic-only papers without clinical-application pathway get desk-rejected within 7-10 days.

Scope-fit ambiguity in the abstract. Diabetes Care editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (diabetes-care research with practice-relevant clinical implications for working endocrinologists and primary-care clinicians). The named failure pattern: mechanistic-only diabetes papers without clinical-application pathway get desk-rejected within 7-10 days. Check whether your abstract reads to Diabetes Care's scope →

Methods package incomplete for the journal's reviewer pool. Diabetes Care reviewers expect specific methodological detail. Trials with pre-specified primary endpoint not matching headline finding extend revision. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. A reference list that cites retracted papers undermines a Diabetes Care submission. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: ScholarOne submission portal. Manuscript constraints for Original Articles: 250-word abstract limit and 4,000-word main-text cap (the editorial office verifies the word count).

We reviewed each of these constraints against current journal author guidelines (accessed 2026-10-09); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights submission-corpus signal for Diabetes Care (American Diabetes Association). Of the manuscripts our team screened before submission to Diabetes Care and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is Diabetes Care editors enforce practice-relevance threshold; mechanistic-only papers without clinical-application pathway get desk-rejected within 7-10 days.

In our analysis of anonymized Diabetes Care-targeted submissions, the documented review timeline shows a bimodal distribution between manuscripts that clear Diabetes Care's scope-fit threshold within the first week and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.

For Diabetes Care, timing matters less than clinical diabetes specificity. The better question is whether the manuscript already behaves like a Diabetes Care paper.

That is why the better next reads are:

• Diabetes Care journal profile

• Diabetes Care submission guide

• Diabetologia submission guide for EASD diabetes manuscripts where Research-in-Context and rapid triage shape timing.

• Diabetes Care citation metrics

• Diabetes Care acceptance rate

A Diabetes Care clinical-fit check is usually more useful than trying to optimize around the median alone.

Diabetes Care review time is best understood as an editorial pathway attached to a selective clinical-diabetes filter. If the manuscript is truly about improving diabetes care, the process can be worth the wait. If not, the wait mostly delays the inevitable journal decision.

The Manusights Diabetes Care readiness scan. This guide tells you what Diabetes Care (American Diabetes Association)'s editors look for in the first editorial read. The review tells you whether your paper passes that check before you submit.

We have reviewed manuscripts targeting Diabetes Care (American Diabetes Association) and peer venues; the named patterns below are the same ones the journal's handling editors and outside reviewers flag at the desk-screen and first-review stages. The journal's About the Journal page lists an average time to first decision of 18 days. 60-day money-back guarantee. Your manuscript is not used for model training, and access is limited to the review workflow.